ABC | Volume 114, Nº3, Março 2020

Posicionamento Posicionamento Brasileiro sobre Hipertensão Arterial Resistente – 2020 Arq Bras Cardiol. 2020; 114(3):576-596 84. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22(11):2217-26. 85. Laragh JH, Sealey JE. The Plasma Renin Test Reveals the Contribution of Body Sodium-Volume Content (V) and Renin–Angiotensin (R) Vasoconstriction to Long-Term Blood Pressure. Am J Hypertens. 2011;24(11):1164-80. 86. Calhoun DA, Booth JN, 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63(3):451-8. 87. Judd EK, Calhoun DA, Warnock DG. Pathophysiology and Treatment of Resistant Hypertension: The Role of Aldosterone and Amiloride-Sensitive Sodium Channels. Semin Nephrol. 2014;34(5):532-9. 88. Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416. 89. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015;66(1):126-33. 90. Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens. 2005;18(12 Pt 1):1631-5. 91. Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007;9(5):353-9. 92. Wang C, Xiong B, Huang J. Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials. Heart Lung Circ. 2016;25(10):1021-30. 93. Jain S, Khera R, Corrales-Medina VF, Townsend RR, Chirinos JA. "Inflammation and arterial stiffness in humans". Atherosclerosis. 2014;237(2):381-90. 94. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-7. 95. Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwinski P, Bielen P, Klisiewicz A, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J HumHypertens. 2013;27(11):678-85. 96. de Faria AP, Modolo R, Fontana V, MorenoH. Adipokines: novel players in resistant hypertension. J ClinHypertens (Greenwich). 2014;16(10):754-9. 97. Lacerda L, Faria AP, Fontana V, Moreno H, Sandrim V. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension. Arq Bras Cardiol. 2015;105(2):168-75. 98. de Faria AP, Ritter AM, Sabbatini AR, Correa NB, Brunelli V, Modolo R, et al. Deregulation of Soluble AdhesionMolecules in Resistant Hypertension and Its Role in Cardiovascular Remodeling. Circ J. 2016;80(5):1196-201. 99. Sabbatini AR, Barbaro NR, de Faria AP, Ritter AMV, Modolo R, Correa NB, etal.Matrixmetalloproteinase-2-735C/Tpolymorphism isassociatedwith resistant hypertension in a specialized outpatient clinic in Brazil. Gene. 2017;620:23-9. 100. Lacchini R, Sabha M, Coeli FB, Favero FF, Yugar-Toledo J, Izidoro-Toledo TC, et al. T allele of -344 C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension. Hypertens Res. 2009;32(2):159-62. 101. Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, CoelhoOR, et al. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011;30(8):555-64. 102. Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, de Haro Moraes C, et al. Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press. 2012;21(1):31-8. 103. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, et al. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011;25(11):656-64. 104. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18(11):1422-8. 105. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-54. 106. Braam B, Taler SJ, Rahman M, Fillaus JA, Greco BA, Forman JP, et al. Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol. 2017;12(3):524-35. 107. Hou H, Zhao Y, Yu W, Dong H, Xue X, Ding J, et al. Association of obstructive sleep apneawith hypertension: A systematic reviewandmeta- analysis. J Glob Health. 2018;8(1):010405. 108. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi- Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005;172(5):613-8. 109. Senaratna CV, Perret JL, MathesonMC, Lodge CJ, Lowe AJ, CassimR, et al. Validity of the Berlin questionnaire in detecting obstructive sleep apnea: A systematic review andmeta-analysis. SleepMed Rev. 2017;36:116-24. 110. Fava C, Dorigoni S, Dalle Vedove F, Danese E, Montagnana M, Guidi GC, et al. Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis. Chest. 2014;145(4):762-71. 111. Guo J, Sun Y, Xue LJ, Huang ZY, Wang YS, Zhang L, et al. Effect of CPAP therapy on cardiovascular events andmortality in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath. 2016;20(3):965-74. 112. Horl MP, Horl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis. 2002;39(2):227-44. 113. Wolley MJ, Stowasser M. Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison. Curr Hypertens Rep. 2016;18(5):36. 114. van Jaarsveld BC, Krijnen P, PietermanH, Derkx FH, Deinum J, Postma CT, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-arterystenosis.DutchRenalArteryStenosis InterventionCooperative Study Group. N Engl J Med. 2000;342(14):1007-14. 115. BavishiC,deLeeuwPW,MesserliFH.AtheroscleroticRenalArteryStenosis and Hypertension: Pragmatism, Pitfalls, and Perspectives. Am J Med. 2016;129(6):635 e5- e14. 116. Van der Niepen P, Rossignol P, Lengele JP, Berra E, Sarafidis P, Persu A. Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not? Curr Hypertens Rep. 2017;19(1):5. 117. Mulherin JL, Jr., Edwards WH. Alternative methods of renal revascularization. Ann Surg. 1987;205(6):740-6. 118. CalhounDA. Isthereanunrecognizedepidemicofprimaryaldosteronism? Pro. Hypertension. 2007;50(3):447-53; discussion -53. 119. Kline GA, Prebtani APH, Leung AA, Schiffrin EL. Primary aldosteronism: a common cause of resistant hypertension. CMAJ. 2017;189(22):E773-E8. 120. Young JWF, CalhounDA, Lenders JWM, StowasserM, Textor SC. Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. Endocrine Rev. 2017;38(2):103-22. 121. Funder JW, Carey RM, Mantero F, MuradMH, ReinckeM, ShibataH, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. 594